Publication Date
March 2025
Start Date
3-8-2025 9:00 AM
End Date
3-8-2025 10:00 AM
Presentation Type
Virtual Poster
Abstract
In NJ, there were no reported errors due to antigen mistyping in 2015-2017. Nationwide, there were no errors due to antigen mistyping reported to the FDA in 2017-2021.
In the US, AABB standards, in accordance with FDA/CFR, do not require secondary testing by the transfusion service of red cell antigens other than ABO and in some cases, RhD. However, some facilities choose to do secondary testing.
Recommended Citation
Hinrichsen, Colleen, "Retesting of Donor Non-ABO/D Red Cell Antigens: Is it Time to Rethink?" (2025).
Franklin University Scholarship Showcase. Paper 14.
Available at: https://fuse.franklin.edu/showcase/2025/presentations/14
Retesting of Donor Non-ABO/D Red Cell Antigens: Is it Time to Rethink?
In NJ, there were no reported errors due to antigen mistyping in 2015-2017. Nationwide, there were no errors due to antigen mistyping reported to the FDA in 2017-2021.
In the US, AABB standards, in accordance with FDA/CFR, do not require secondary testing by the transfusion service of red cell antigens other than ABO and in some cases, RhD. However, some facilities choose to do secondary testing.